Probi has signed an extension to the long term distribution agreement with Health World Limited, Australia and New Zealand´s market leading probiotic provider. Health World, being Probi´s first partner in the Consumer Healthcare business has successfully been selling Probi Digestis®for 8 years and Health World will now extend their product offering by adding Probi´s immune product Probi Defendum® to their range.The launch is scheduled for Q1 2014. “We are very happy to broaden the successful long-term collaboration with Health World to also include the Probi Defendum® product. Health World, being the leading player in the Australian probiotic market, is the ideal partner for us” says Gun-Britt Fransson, interim CEO of Probi. “After years of successful sales and marketing of Probi Digestis® we are happy to add a new probiotic concept from Probi, Probi Defendum®. In line with Probi´s proven R&D strategy the product has good and solid clinical documentation. We are looking forward to continue the close collaboration with Probi and take part in Probi´s growing probiotic pipeline” Says Graeme Joiner, Director of Sales & Marketing, Health World. Probi Defendum® is based on the combination of two probiotic strains, Lactobacillus plantarum HEAL9 and Lactobacillus paracasei 8700:2. It has been proven in large clinical studies to prevent common colds, significantly reduce cold symptoms and shorten cold periods. The information is such that Probi AB must disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. FOR FURTHER INFORMATION, CONTACT: Gun-Britt Fransson, interim CEO, Probi, phone. +46 46 286 89 74 or mobile +46 705 95 73 27, e-mail: Gun-Britt.Fransson@probi.se Niklas Bjärum, Vice President Marketing & Sales, Probi, phone. +46 46 286 89 67 or, mobile: +46 705 38 88 64, e-mail: niklas.bjarum@probi.se ABOUT PROBI Probi is a leading player in the probiotic research and the development of efficient and well-documented probiotics. The research areas include: gastrointestinal tracts, immune system, metabolic syndrome and stress and recovery. Probi’s customers are leading companies in the Functional Foods and Consumer Healthcare segments. Total income for 2012 was MSEK 100.4. Probi’s share is listed on the Nasdaq OMX Stockholm, Small Cap. Probi has approximately 5,000 shareholders. Read more on www.probi.com. ABOUT HEALTH WORLD Health World is a leading supplier of natural medicines in Australia and New Zealand by providing high quality, effective products based on the latest scientific research. Health World ensures product quality, safety and efficacy by strictly analysing and testing their products on site at their purpose built manufacturing facility in Northgate, Queensland.
Probi extends the collaboration with Health World Australia
Top 10 Most Recent News Articles
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances
A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...
Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation
Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...
Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal
A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...
Continue Reading
Southern Company Sparks Swift Power Restoration Post-Isaias
Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...
Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data
Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...
Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps
Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...
Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight
A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...
Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight
First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...
Continue Reading
AI Drives Major Time Savings in Endoscopy Tech
AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...
Continue Reading
NARUTO Card Game Set for June 2027 Global Launch
Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...
Continue ReadingTop 5 Most Recently Viewed Articles
Understanding Credit Card Interest Rates and How to Manage Them
Understanding Credit Card Interest Rates Recently, the average credit card interest rate has climbed to 22.63%, a notable rise from the previous average of 16.98%. The interest rate you face can vary widely based on the type of credit card and your individual credit profile. By understanding how credit card annual percentage rates (APR) work, you can potentially reduce...
Continue Reading
Hexaware Reports Strong Q3CY25 Performance with Revenue Rise
Hexaware Technologies Financial Results Overview Hexaware Technologies (NSE: HEXT) has showcased impressive performance for the third quarter of calendar year 2025, with total revenue reaching USD 394.8 million. This figure marks a noteworthy increase of 5.5% year-over-year, showcasing the company's resilience and ability to navigate market challenges effectively....
Continue Reading
Alm. Brand A/S Reports Progress in Share Buybacks for 2024
Overview of Alm. Brand A/S Share Buy-Back Program Alm. Brand A/S has kicked off an ambitious share buy-back program, looking to acquire shares totaling up to DKK 150 million. This initiative was officially announced earlier, providing insight into the year's financial strategy. Recent Transactions Under the Program During the week starting 9 September 2024 and ending on...
Continue Reading
NRx Pharmaceuticals Adjusts Release Date for Q2 Financials
NRx Pharmaceuticals Announces Rescheduled Q2 2025 Financial Results Release NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) recently made an exciting announcement regarding the release of its second quarter 2025 financial results. The company has decided to delay the publication of these results to ensure a more comprehensive presentation for its stakeholders. This update comes...
Continue Reading
Top 5 Stocks to Watch for a Market Pullback Soon
Understanding Market Pullbacks As major U.S. stock indices reached unprecedented levels recently, the optimism surrounding potential Federal Reserve rate cuts has driven prices higher. However, the surge seems excessive given the realistically anticipated modest decrease in rates. This opens a window for investors to reassess their portfolios, particularly those holdings...
Continue Reading